Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
DICE Therapeutics, Inc. (DICE)
|
Add to portfolio |
|
|
|
| Price: |
$23.19
| | Metrics |
| OS: |
47.8
|
M
| |
|
|
| Market cap: |
$1.11
|
B
| |
|
|
|
Net cash:
|
$73.5
|
M
| |
$1.54
|
per share
|
|
EV:
|
$1.03
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($1.87)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 62.6 | 1.1 | 36.5 | 0.9 | 15.7 |
| Revenue growth | -100.0% | 71.4% | 30.4% | | -94.5% | |
| Cost of goods sold | 0.0 | 88.2 | 0.0 | 48.7 | 0.0 | 25.7 |
| Gross profit | 0.0 | -25.7 | 1.1 | -12.2 | 0.9 | -9.9 |
| Gross margin | | -41.0% | 100.0% | -33.5% | 100.0% | -63.3% |
| Selling, general and administrative | 88.2 | | 48.7 | | | |
| Research and development | | | | | 19.6 | |
| General and administrative | | 25.7 | | 12.2 | 5.0 | 3.6 |
| EBIT | 0.0 | -88.2 | -47.6 | -47.6 | -23.7 | -13.5 |
| EBIT margin | | -141.0% | -4234.8% | -130.4% | -2748.7% | -86.2% |
| Pre-tax income | -83.9 | -83.9 | -49.0 | -49.0 | -23.7 | -12.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -83.9 | -83.9 | -49.0 | -49.0 | -23.7 | -12.9 |
| Net margin | | -134.1% | -4351.9% | -134.1% | -2750.8% | -82.3% |
| |
| Diluted EPS | ($2.13) | ($2.13) | ($3.95) | ($3.95) | ($10.56) | ($5.75) |
| Shares outstanding (diluted) | 39.4 | 39.4 | 12.4 | 12.4 | 2.2 | 2.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|